Literature DB >> 12394782

HIV-1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes.

Eric Anderson1, Walter Zink, Huangui Xiong, Howard E Gendelman.   

Abstract

Infection of the nervous system by HIV-1 commonly causes a broad range of cognitive, behavioral, and motor abnormalities called, in its most severe form, HIV-1-associated dementia (HAD). HAD is a metabolic encephalopathy caused by productive viral infection of brain mononuclear phagocytes (MPs) (perivascular and parenchymal brain macrophages and microglia) and sustained by paracrine-amplified, inflammatory, neurotoxic responses. MP neurotoxins are, in large measure, homeostatic secretory products that can have a negative effect on neuronal cell function when produced in abundance. Proinflammatory cytokines, chemokines, platelet-activating factor, arachidonic acid and its metabolites, nitric oxide, quinolinic acid, progeny virions, and viral structural and regulatory proteins are all included as part of these cellular and viral toxic elements. In addition, neuronal damage can occur directly by engaging specific receptors or through inducing widespread inflammatory activities in brain tissue that ultimately induce neuronal demise. The mechanisms for immune-and viral-mediated neural injury in HAD are made more striking by the effects of abused drugs on cognitive function. Ultimately, linkages between neuronal function and disordered MP immunity will provide insights into how HIV-1 infection of the brain leads to compromised mental function as well as providing clues into the pathogenesis of other neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12394782     DOI: 10.1097/00126334-200210012-00004

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  62 in total

1.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

Review 2.  Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals.

Authors:  Uraina S Clark; Ronald A Cohen
Journal:  Curr Opin Investig Drugs       Date:  2010-08

3.  Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders.

Authors:  Jenna M Puccini; Daniel F Marker; Tim Fitzgerald; Justin Barbieri; Christopher S Kim; Patrick Miller-Rhodes; Shao-Ming Lu; Stephen Dewhurst; Harris A Gelbard
Journal:  J Neurosci       Date:  2015-04-01       Impact factor: 6.167

4.  Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.

Authors:  Pawel Ciborowski
Journal:  Biomark Med       Date:  2009-12       Impact factor: 2.851

5.  Regional cortical thinning associated with detectable levels of HIV DNA.

Authors:  Kalpana J Kallianpur; Gregory R Kirk; Napapon Sailasuta; Victor Valcour; Bruce Shiramizu; Beau K Nakamoto; Cecilia Shikuma
Journal:  Cereb Cortex       Date:  2011-10-19       Impact factor: 5.357

6.  Activation of HIV-1 LTR by Rad51 in microglial cells.

Authors:  Inna Rom; Armine Darbinyan; Martyn K White; Jay Rappaport; Bassel E Sawaya; Shohreh Amini; Kamel Khalili
Journal:  Cell Cycle       Date:  2010-09-07       Impact factor: 4.534

7.  Neuroprotective activities of CEP-1347 in models of neuroAIDS.

Authors:  Dawn Eggert; Prasanta K Dash; Santhi Gorantla; Huanyu Dou; Giovanni Schifitto; Sanjay B Maggirwar; Stephen Dewhurst; Larisa Poluektova; Harris A Gelbard; Howard E Gendelman
Journal:  J Immunol       Date:  2009-12-04       Impact factor: 5.422

Review 8.  NeuroAIDS: characteristics and diagnosis of the neurological complications of AIDS.

Authors:  Alireza Minagar; Deborah Commins; J Steven Alexander; Romy Hoque; Francesco Chiappelli; Elyse J Singer; Behrooz Nikbin; Paul Shapshak
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

9.  Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection.

Authors:  Lars Hagberg; Paola Cinque; Magnus Gisslen; Bruce J Brew; Serena Spudich; Arabella Bestetti; Richard W Price; Dietmar Fuchs
Journal:  AIDS Res Ther       Date:  2010-06-03       Impact factor: 2.250

10.  Contribution of CNS cells in NeuroAIDS.

Authors:  Ashish Swarup Verma; Udai Pratap Singh; Premendra Dhar Dwivedi; Anchal Singh
Journal:  J Pharm Bioallied Sci       Date:  2010-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.